<p><strong><em>公司扩展知识产权组合，同时推进肿瘤支持治疗的临床创新</em></strong></p>
<p><strong><em>案例研究和中期临床试验结果将被讨论</em></strong></p>
<p>, /PRNewswire/ -- <strong><em>Hoth Therapeutics, Inc.</em> (NASDAQ: HOTH</strong>)，一家临床阶段的生物制药公司，致力于开发突破性疗法以改善患者生活，今天宣布将举行一场关键意见领袖（KOL）活动，展示其新型局部治疗药物 HT-001，旨在治疗由 EGFR 抑制剂癌症疗法引起的严重皮肤毒性。</p>
<p><img src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/644804/Hoth_Therapeutics_Logo.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/644804/Hoth_Therapeutics_Logo.jpg"/></p>
<p>这些常见的治疗限制性副作用——如皮疹和炎症——常常迫使患者减少或停止可能挽救生命的癌症治疗。HT-001 提供了一种针对性的解决方案，旨在保护患者的生活质量，并确保他们能够继续接受关键的肿瘤治疗。</p>
<ul>
<li>2024 年，整体化疗药物市场的估值为 108.7 亿美元，预计到 2031 年将达到 183.5 亿美元。这个市场中有相当一部分将涉及经历皮肤毒性的患者。*</li>
<li>支持性护理需求：化疗治疗的增加自然推动了对支持性护理药物的需求，以管理副作用，包括皮肤皮疹。*</li>
<li>未满足的需求：虽然存在支持性护理药物，但化疗引起的皮肤皮疹，特别是像肢端红斑（手足综合症）这样的情况，可能是严重和虚弱的，这突显了新型或改进治疗选择的潜力。*</li>
</ul>
<p>Hoth Therapeutics 的首席执行官 Robb Knie 表示：“HT-001 是针对因 EGFR 疗法而遭受皮肤毒性的癌症患者的首个此类治疗。我们很高兴能展示突破性的案例研究和中期 2a 期结果。我们相信我们的数据突显了 HT-001 的强大安全性，并有潜力在这一服务不足的领域设定新的护理标准。”</p>
<p>即将举行的活动将邀请皮肤肿瘤学和皮肤科专家 Jonathan Hale Zippin M.D., Ph.D.和 Adam Friedman, M.D., F.A.A.D.进行专家评论，他们将强调 HT-001 在癌症护理中的紧迫临床需求和有希望的作用，包括初步数据结果，显示在 HT-001 的开放标签队列中安全性和有效性。投资者将深入了解 HT-001 如何重塑癌症相关皮肤副作用的治疗格局，并成为肿瘤科医生在给患者开处方 EGFR 抑制剂时使用的预防性治疗选择。</p>
<p>随着临床进展，Hoth 最近收到了美国专利商标局的申请收据，涵盖 HT-001 独特配方的新专利申请——进一步加强了其扩展的知识产权组合和对该资产的战略市场保护。</p>
<p><strong>主要亮点：</strong></p>
<ul>
<li>通过 HT-001 解决未满足的需求</li>
<li>强大的知识产权战略正在进行中，扩展对 HT-001 的保护</li>
<li>有效的作用机制以治疗 EGFR 抑制剂引起的毒性</li>
<li>即将讨论的临床和开发里程碑将在 KOL 活动中介绍</li>
</ul>
<p>KOL 活动还将提供 Hoth 的管道进展、知识产权战略和正在进行的 2 期试验的更新。</p>
<p>投资者、媒体和潜在合作伙伴以及医疗专业人士被邀请参加此次活动，关于如何参加的信息将在活动日期临近时发布，活动定于 2025 年 6 月 24 日下午 3:30（东部时间）。</p>
<p>*=https://www.biospace.com/press-releases/chemotherapy-market-size-to-reach-usd-18-35-billion-by-2031#:~:text=Chemotherapy%20Market%20Opportunity:%20Rising%20Cancer,in%20increased%20demand%20for%20chemotherapy.</p>
<p><strong>关于 Hoth Therapeutics, Inc.</strong></p>
<p>Hoth Therapeutics 是一家临床阶段的生物制药公司，致力于开发创新、具有影响力和突破性的治疗，旨在改善患者的生活质量。我们是早期制药研究和开发的催化剂，将药物从实验室提升到临床前和临床测试。我们采用以患者为中心的方法，与科学家、临床医生和关键意见领袖团队合作，寻求和研究具有巨大潜力的疗法，以创造突破并多样化治疗选择。欲了解更多信息，请访问 https://ir.hoththerapeutics.com/.</p>
<p><strong>前瞻性声明</strong></p>
<p>本新闻稿包含基于 Hoth 当前预期的前瞻性声明，这些声明可能构成 1995 年《私人证券诉讼改革法案》及其他联邦证券法下安全港条款的前瞻性声明，并且受到重大风险、不确定性和假设的影响。这些声明涉及 Hoth 的商业战略；监管提交的时间；获得和维持现有产品候选者及我们可能开发的任何其他产品候选者的监管批准的能力，以及我们可能获得的任何批准下的标签；临床试验的时间和成本，以及其他费用的时间和成本；我们产品的市场接受度；任何健康流行病对我们业务、临床试验、研究项目、医疗系统或全球经济整体的最终影响；我们的知识产权；我们对第三方组织的依赖；我们的竞争地位；我们的行业环境；我们预期的财务和运营结果，包括预期的收入来源；我们对可用市场规模、产品收益、产品定价和产品推出时间的假设；管理层对未来收购的预期；关于我们的目标、意图、计划和预期的声明，包括新产品和市场的推出；以及我们的现金需求和融资计划。有许多因素可能导致实际事件与这些前瞻性声明所指示的情况存在重大差异。您不应依赖这些前瞻性声明，这些声明包含诸如 “可能”、“相信”、“预期”、“打算”、“估计”、“期望”、“可能”、“继续”、“预测”、“潜在”、“项目” 或类似术语、这些术语的变体或这些术语的否定形式。尽管公司相信前瞻性声明中反映的预期是合理的，但公司无法保证这些结果。Hoth 可能无法实现其预期，其信念可能并不正确。实际结果可能因各种重要因素而与这些前瞻性声明所指示的情况存在重大差异，包括但不限于市场条件以及在 Hoth 最近的 10-K 表格年度报告和 Hoth 向美国证券交易委员会提交的其他文件中描述的因素。所有这些声明仅在作出时有效。因此，前瞻性声明应仅被视为 Hoth 当前的计划、估计和信念。投资者不应对前瞻性声明过度依赖。Hoth 无法保证未来的结果、事件、活动水平、表现或成就。Hoth 不承担并特别拒绝任何更新、重新发布或修订任何前瞻性声明的义务，以反映新信息、未来事件或情况，或反映意外事件的发生，除非适用法律要求。</p>
<p><strong>投资者联系：</strong> LR Advisors LLC</p>
<p>电子邮件：investorrelations@hoththerapeutics.com</p>
<p>www.hoththerapeutics.com</p>
<p>电话：（678）570-6791</p>
<p>来源：Hoth Therapeutics, Inc.</p>

HOTH

<p>Hoth Therapeutics, Inc.（纳斯达克股票代码：HOTH）将举办一场关键意见领袖（KOL）活动，展示 HT-001，这是一种针对 EGFR 抑制剂癌症疗法引起的皮肤毒性的创新外用治疗。此次活动将讨论临床试验的中期结果以及肿瘤学中对支持性护理的未满足需求。首席执行官 Robb Knie 强调了 HT-001 设定新护理标准的潜力。公司还通过新的专利申请扩展了其知识产权组合。活动定于 2025 年 6 月 24 日下午 3:30（东部时间）举行，邀请投资者和医疗专业人士参加</p>

<p><strong><em>Company Expands IP Portfolio While Advancing Clinical Innovation in Oncology Supportive Care</em></strong></p>
<div class="lb-trans"><p><strong><em>公司扩展知识产权组合，同时推进肿瘤支持治疗的临床创新</em></strong></p>
</div><p><strong><em>Case Study and Interim Clinical Trial Results Will Be Discussed</em></strong></p>
<div class="lb-trans"><p><strong><em>案例研究和中期临床试验结果将被讨论</em></strong></p>
</div><p>, /PRNewswire/ -- <strong><em>Hoth Therapeutics, Inc.</em> (NASDAQ: HOTH</strong>), a clinical-stage biopharmaceutical company pioneering breakthrough therapies to improve the lives of patients, today announced a Key Opinion Leader (KOL) event showcasing HT-001, its novel topical therapeutic, designed to treat debilitating skin toxicities caused by EGFR inhibitor cancer therapies.</p>
<div class="lb-trans"><p>, /PRNewswire/ -- <strong><em>Hoth Therapeutics, Inc.</em> (NASDAQ: HOTH</strong>)，一家临床阶段的生物制药公司，致力于开发突破性疗法以改善患者生活，今天宣布将举行一场关键意见领袖（KOL）活动，展示其新型局部治疗药物 HT-001，旨在治疗由 EGFR 抑制剂癌症疗法引起的严重皮肤毒性。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/644804/Hoth_Therapeutics_Logo.jpg" alt="" original-src="https://mma.prnewswire.com/media/644804/Hoth_Therapeutics_Logo.jpg"/></p>
<p>These common treatment-limiting side effects—such as rash and inflammation—often force patients to reduce or stop potentially life-saving cancer therapy. HT-001 offers a targeted solution aimed at protecting patients' quality of life and ensuring continued access to their critical oncology treatments.</p>
<div class="lb-trans"><p>这些常见的治疗限制性副作用——如皮疹和炎症——常常迫使患者减少或停止可能挽救生命的癌症治疗。HT-001 提供了一种针对性的解决方案，旨在保护患者的生活质量，并确保他们能够继续接受关键的肿瘤治疗。</p>
</div><ul>
<li>The overall chemotherapy drug market was valued at USD 10.87 billion in 2024 and is expected to reach USD 18.35 billion by 2031. A significant portion of this market will involve patients who experience skin toxicities.*</li>
<li>Supportive care needs: The rise in chemotherapy treatments naturally drives demand for supportive care drugs to manage side effects, including skin rashes.*</li>
<li>Unmet needs: While supportive care drugs exist, chemotherapy-induced skin rash, particularly conditions like Acral erythema (hand-foot syndrome), can be severe and debilitating, highlighting the potential for novel or improved treatment options.*</li>
</ul>
<div class="lb-trans"><ul>
<li>2024 年，整体化疗药物市场的估值为 108.7 亿美元，预计到 2031 年将达到 183.5 亿美元。这个市场中有相当一部分将涉及经历皮肤毒性的患者。*</li>
<li>支持性护理需求：化疗治疗的增加自然推动了对支持性护理药物的需求，以管理副作用，包括皮肤皮疹。*</li>
<li>未满足的需求：虽然存在支持性护理药物，但化疗引起的皮肤皮疹，特别是像肢端红斑（手足综合症）这样的情况，可能是严重和虚弱的，这突显了新型或改进治疗选择的潜力。*</li>
</ul>
</div><p>Robb Knie, CEO of Hoth Therapeutics, remarked &#34;HT-001 Presents the first of its kind treatment for cancer patients suffering with skin toxicities associated with EGFR therapies. We are excited to present the groundbreaking case study and interim Phase 2a results. We believe ourdata highlights HT-001's strong safety profile and the potential for it to set a new standard of care in this underserved area.&#34;</p>
<div class="lb-trans"><p>Hoth Therapeutics 的首席执行官 Robb Knie 表示：“HT-001 是针对因 EGFR 疗法而遭受皮肤毒性的癌症患者的首个此类治疗。我们很高兴能展示突破性的案例研究和中期 2a 期结果。我们相信我们的数据突显了 HT-001 的强大安全性，并有潜力在这一服务不足的领域设定新的护理标准。”</p>
</div><p>The upcoming event will feature expert commentary from leading derm-oncology and dermatology specialists Jonathan Hale Zippin M.D., Ph.D.and Adam Friedman, M.D., F.A.A.D., who will highlight the urgent clinical need and the promising role of HT-001 in cancer care, including the preliminary data results showing safety and efficacy in the open-label cohort of the ongoing clinical trial for HT-001. Investors will gain an inside look at how HT-001 could reshape the treatment landscape for cancer-related dermatologic side effects and become a prophylactic treatment option used by oncologists prescribing EGFR inhibitors to patients.</p>
<div class="lb-trans"><p>即将举行的活动将邀请皮肤肿瘤学和皮肤科专家 Jonathan Hale Zippin M.D., Ph.D.和 Adam Friedman, M.D., F.A.A.D.进行专家评论，他们将强调 HT-001 在癌症护理中的紧迫临床需求和有希望的作用，包括初步数据结果，显示在 HT-001 的开放标签队列中安全性和有效性。投资者将深入了解 HT-001 如何重塑癌症相关皮肤副作用的治疗格局，并成为肿瘤科医生在给患者开处方 EGFR 抑制剂时使用的预防性治疗选择。</p>
</div><p>In tandem with clinical momentum, Hoth recently received a USPTO Filing Receipt for a new patent application covering HT-001's unique formulation—further reinforcing its expanding intellectual property portfolio and strategic market protection for this asset.</p>
<div class="lb-trans"><p>随着临床进展，Hoth 最近收到了美国专利商标局的申请收据，涵盖 HT-001 独特配方的新专利申请——进一步加强了其扩展的知识产权组合和对该资产的战略市场保护。</p>
</div><p><strong>Key Highlights:</strong></p>
<div class="lb-trans"><p><strong>主要亮点：</strong></p>
</div><ul>
<li>Addressing an unmet need with HT-001</li>
<li>Strong IP strategy underway, expanding protection around HT-001</li>
<li>Compelling mechanism of action to treat EGFR-inhibitor-induced toxicities</li>
<li>Near-term clinical and development milestones to be discussed at the KOL event</li>
</ul>
<div class="lb-trans"><ul>
<li>通过 HT-001 解决未满足的需求</li>
<li>强大的知识产权战略正在进行中，扩展对 HT-001 的保护</li>
<li>有效的作用机制以治疗 EGFR 抑制剂引起的毒性</li>
<li>即将讨论的临床和开发里程碑将在 KOL 活动中介绍</li>
</ul>
</div><p>The KOL event will also provide an update on Hoth's pipeline progress, IP strategy, and Phase 2 trial that is underway.</p>
<div class="lb-trans"><p>KOL 活动还将提供 Hoth 的管道进展、知识产权战略和正在进行的 2 期试验的更新。</p>
</div><p>Investors, media, and potential partners along with healthcare professionals are invited to attend this event, information on how to join will be released as we near the event date, June 24, 2025, at 3:30PM EST.</p>
<div class="lb-trans"><p>投资者、媒体和潜在合作伙伴以及医疗专业人士被邀请参加此次活动，关于如何参加的信息将在活动日期临近时发布，活动定于 2025 年 6 月 24 日下午 3:30（东部时间）。</p>
</div><p>*=https://www.biospace.com/press-releases/chemotherapy-market-size-to-reach-usd-18-35-billion-by-2031#:~:text=Chemotherapy%20Market%20Opportunity:%20Rising%20Cancer,in%20increased%20demand%20for%20chemotherapy.</p>
<div class="lb-trans"><p>*=https://www.biospace.com/press-releases/chemotherapy-market-size-to-reach-usd-18-35-billion-by-2031#:~:text=Chemotherapy%20Market%20Opportunity:%20Rising%20Cancer,in%20increased%20demand%20for%20chemotherapy.</p>
</div><p><strong>About Hoth Therapeutics, Inc.</strong></p>
<div class="lb-trans"><p><strong>关于 Hoth Therapeutics, Inc.</strong></p>
</div><p>Hoth Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative, impactful, and ground-breaking treatments with a goal to improve patient quality of life. We are a catalyst in early-stage pharmaceutical research and development, elevating drugs from the bench to pre-clinical and clinical testing. Utilizing a patient-centric approach, we collaborate and partner with a team of scientists, clinicians, and key opinion leaders to seek out and investigate therapeutics that hold immense potential to create breakthroughs and diversify treatment options. To learn more, please visit https://ir.hoththerapeutics.com/.</p>
<div class="lb-trans"><p>Hoth Therapeutics 是一家临床阶段的生物制药公司，致力于开发创新、具有影响力和突破性的治疗，旨在改善患者的生活质量。我们是早期制药研究和开发的催化剂，将药物从实验室提升到临床前和临床测试。我们采用以患者为中心的方法，与科学家、临床医生和关键意见领袖团队合作，寻求和研究具有巨大潜力的疗法，以创造突破并多样化治疗选择。欲了解更多信息，请访问 https://ir.hoththerapeutics.com/.</p>
</div><p><strong>Forward-LookingStatement</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明</strong></p>
</div><p>This press release includes forward-looking statements based upon Hoth's current expectations, which may constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws, and are subject to substantial risks, uncertainties, and assumptions. These statements concern Hoth's business strategies; the timing of regulatory submissions; the ability to obtain and maintain regulatory approval of existing product candidates and any other product candidates we may develop, and the labeling under any approval we may obtain; the timing and costs of clinical trials, and the timing and costs of other expenses; market acceptance of our products; the ultimate impact of any health epidemic, on our business, our clinical trials, our research programs, healthcare systems, or the global economy as a whole; our intellectual property; our reliance on third-party organizations; our competitive position; our industry environment; our anticipated financial and operating results, including anticipated sources of revenues; our assumptions regarding the size of the available market, benefits of our products, product pricing, and timing of product launches; management's expectation with respect to future acquisitions; statements regarding our goals, intentions, plans, and expectations, including the introduction of new products and markets; and our cash needs and financing plans. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. You should not place reliance on these forward-looking statements, which include words such as &#34;could,&#34; &#34;believe,&#34; &#34;anticipate,&#34; &#34;intend,&#34; &#34;estimate,&#34; &#34;expect,&#34; &#34;may,&#34; &#34;continue,&#34; &#34;predict,&#34; &#34;potential,&#34; &#34;project&#34; or similar terms, variations of such terms, or the negative of those terms. Although the company believes that the expectations reflected in the forward-looking statements are reasonable, the company cannot guarantee such outcomes. Hoth may not realize its expectations, and its beliefs may not prove correct. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, market conditions and the factors described in the section titled &#34;Risk Factors&#34; in Hoth's most recent Annual Report on Form 10-K and Hoth's other filings made with the U. S. Securities and Exchange Commission. All such statements speak only as of the date made. Consequently, forward-looking statements should be regarded solely as Hoth's current plans, estimates, and beliefs. Investors should not place undue reliance on forward-looking statements. Hoth cannot guarantee future results, events, levels of activity, performance, or achievements. Hoth does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events, or circumstances or to reflect the occurrences of unanticipated events, except as may be required by applicable law.</p>
<div class="lb-trans"><p>本新闻稿包含基于 Hoth 当前预期的前瞻性声明，这些声明可能构成 1995 年《私人证券诉讼改革法案》及其他联邦证券法下安全港条款的前瞻性声明，并且受到重大风险、不确定性和假设的影响。这些声明涉及 Hoth 的商业战略；监管提交的时间；获得和维持现有产品候选者及我们可能开发的任何其他产品候选者的监管批准的能力，以及我们可能获得的任何批准下的标签；临床试验的时间和成本，以及其他费用的时间和成本；我们产品的市场接受度；任何健康流行病对我们业务、临床试验、研究项目、医疗系统或全球经济整体的最终影响；我们的知识产权；我们对第三方组织的依赖；我们的竞争地位；我们的行业环境；我们预期的财务和运营结果，包括预期的收入来源；我们对可用市场规模、产品收益、产品定价和产品推出时间的假设；管理层对未来收购的预期；关于我们的目标、意图、计划和预期的声明，包括新产品和市场的推出；以及我们的现金需求和融资计划。有许多因素可能导致实际事件与这些前瞻性声明所指示的情况存在重大差异。您不应依赖这些前瞻性声明，这些声明包含诸如 “可能”、“相信”、“预期”、“打算”、“估计”、“期望”、“可能”、“继续”、“预测”、“潜在”、“项目” 或类似术语、这些术语的变体或这些术语的否定形式。尽管公司相信前瞻性声明中反映的预期是合理的，但公司无法保证这些结果。Hoth 可能无法实现其预期，其信念可能并不正确。实际结果可能因各种重要因素而与这些前瞻性声明所指示的情况存在重大差异，包括但不限于市场条件以及在 Hoth 最近的 10-K 表格年度报告和 Hoth 向美国证券交易委员会提交的其他文件中描述的因素。所有这些声明仅在作出时有效。因此，前瞻性声明应仅被视为 Hoth 当前的计划、估计和信念。投资者不应对前瞻性声明过度依赖。Hoth 无法保证未来的结果、事件、活动水平、表现或成就。Hoth 不承担并特别拒绝任何更新、重新发布或修订任何前瞻性声明的义务，以反映新信息、未来事件或情况，或反映意外事件的发生，除非适用法律要求。</p>
</div><p><strong>Investor Contact:</strong> LR Advisors LLC</p>
<div class="lb-trans"><p><strong>投资者联系：</strong> LR Advisors LLC</p>
</div><p>Email:investorrelations@hoththerapeutics.com</p>
<div class="lb-trans"><p>电子邮件：investorrelations@hoththerapeutics.com</p>
</div><p>www.hoththerapeutics.com</p>
<div class="lb-trans"><p>www.hoththerapeutics.com</p>
</div><p>Phone:(678) 570-6791</p>
<div class="lb-trans"><p>电话：（678）570-6791</p>
</div><p>SOURCE Hoth Therapeutics, Inc.</p>
<div class="lb-trans"><p>来源：Hoth Therapeutics, Inc.</p>
</div>

Hoth Therapeutics to Spotlight HT-001 in Investor-Focused KOL Event Addressing Breakthrough Combating Cancer Treatment Skin Toxicities | HOTH Stock News

Hoth Therapeutics 将在面向投资者的 KOL 活动中重点介绍 HT-001，讨论突破性解决抗癌治疗皮肤毒性的问题 | HOTH 股票新闻